» Articles » PMID: 35925428

Metabolic Targeting of Malignant Tumors: a Need for Systemic Approach

Overview
Specialty Oncology
Date 2022 Aug 4
PMID 35925428
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Dysregulated metabolism is now recognized as a fundamental hallmark of carcinogenesis inducing aggressive features and additional hallmarks. In this review, well-established metabolic changes displayed by tumors are highlighted in a comprehensive manner and corresponding therapeutical targets are discussed to set up a framework for integrating basic research findings with clinical translation in oncology setting.

Methods: Recent manuscripts of high research impact and relevant to the field from PubMed (2000-2021) have been reviewed for this article.

Results: Metabolic pathway disruption during tumor evolution is a dynamic process potentiating cell survival, dormancy, proliferation and invasion even under dismal conditions. Apart from cancer cells, though, tumor microenvironment has an acting role as extracellular metabolites, pH alterations and stromal cells reciprocally interact with malignant cells, ultimately dictating tumor-promoting responses, disabling anti-tumor immunity and promoting resistance to treatments.

Conclusion: In the field of cancer metabolism, there are several emerging prognostic and therapeutic targets either in the form of gene expression, enzyme activity or metabolites which could be exploited for clinical purposes; both standard-of-care and novel treatments may be evaluated in the context of metabolism rewiring and indeed, synergistic effects between metabolism-targeting and other therapies would be an attractive perspective for further research.

Citing Articles

Effect of Narrative Nursing Intervention on Patients with Specific Digestive Tract Malignancies (Esophageal, Gastric, and Intestinal Cancers): A Retrospective Study.

Zheng Y Int J Gen Med. 2024; 17:5747-5756.

PMID: 39650786 PMC: 11624947. DOI: 10.2147/IJGM.S489001.


Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment.

Silva A, Moura I, da Gama M, Leal L, Pinho S, Espinoza B Vaccines (Basel). 2023; 11(8).

PMID: 37631922 PMC: 10458729. DOI: 10.3390/vaccines11081354.

References
1.
Achreja A, Zhao H, Yang L, Yun T, Marini J, Nagrath D . Exo-MFA - A 13C metabolic flux analysis framework to dissect tumor microenvironment-secreted exosome contributions towards cancer cell metabolism. Metab Eng. 2017; 43(Pt B):156-172. PMC: 7393794. DOI: 10.1016/j.ymben.2017.01.001. View

2.
Adekola K, Rosen S, Shanmugam M . Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012; 24(6):650-4. PMC: 6392426. DOI: 10.1097/CCO.0b013e328356da72. View

3.
Allen E, Mieville P, Warren C, Saghafinia S, Li L, Peng M . Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell Rep. 2016; 15(6):1144-60. PMC: 4872464. DOI: 10.1016/j.celrep.2016.04.029. View

4.
Allen E, Ulanet D, Pirman D, Mahoney C, Coco J, Si Y . Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. Cell Rep. 2016; 17(3):876-890. DOI: 10.1016/j.celrep.2016.09.052. View

5.
Amendola C, Mahaffey J, Parker S, Ahearn I, Chen W, Zhou M . KRAS4A directly regulates hexokinase 1. Nature. 2019; 576(7787):482-486. PMC: 6923592. DOI: 10.1038/s41586-019-1832-9. View